… In this review, we aimed to summarize some important facts on the JAK/STAT signaling
pathway during SARS-CoV-2 infection and the potential benefit of JAK inhibitors on the clinical …

… but the risk of Janus kinase inhibitor (JAKi) treatment has not been addressed. In light of …
SARS-CoV-2, and such toxicities are all but absent. Table IRate of infections with Janus kinase …

… inhibition of Janus kinase-mediated cytokine signaling using ruxolitinib is feasible and
efficacious in SARS-CoV-2- induced ARDS with hyperinflammation. Sixteen SARS-CoV-2 …

… SARS-CoV-2 infection. We strongly agree that there may be a role for JAK inhibitors in treating
SARS-CoV… mice infected with the original SARS virus, SARS-CoV, that a suboptimal early …

… Recently, the combination therapy of Janus kinase (JAK) inhibitor baricitinib has been
authorized for emergency COVID-19 hospitalized patients; however, this strategy's safety, drug-…

… NF-κB activating kinase (NAK) family [13,14,15]. This article provides an overview of the
mechanism of baricitinib for the treatment of SARS-CoV-2 pneumonia. JAK/signal transducers …

… Our study objective was to investigate the presumed attenuated humoral response to
vaccination against SARS-CoV-2 in patients with RA treated with Janus kinase (JAK) inhibitors with …

… Acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection continues to be a …
SARS-CoV-2 infection, the current review focuses on the role of activated Janus kinase (JAK) …

… In general, we observed that JAK inhibitors were well tolerated with a low rate of complications.
Clot risk during infection with SARS-CoV-2 is well described and mechanisms include …

… upon SARS-CoV-2 infection. Furthermore, chemical inhibition of JAK kinases enhanced
infection … cultures, indicating that the virus benefits from inhibiting the JAK-STAT pathway. These …